High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant.

William C ShropshireBradley T EndresJovan BorjanSamuel L AitkenWilliam C BachmanChristi L McElhenyChin-Ting WuStephanie L EggeAyesha KhanWilliam R MillerMicah M BhattiPranoti SaharasbhojaneAkito Kawai Ryan K Shields Samuel A Shelburne Iii Yohei Doi

Published in: The Journal of antimicrobial chemotherapy (2023)

We identified ceftazidime/avibactam resistance in E. coli associated with a novel CMY variant. Unlike other AmpC enzymes, CMY-185 appears to require an additional substitution on top of N346Y to confer ceftazidime/avibactam resistance.

Keyphrases

gram negative
escherichia coli
klebsiella pneumoniae
multidrug resistant
crispr cas
staphylococcus aureus
candida albicans